Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro.
10.3802/jgo.2011.22.4.225
- Author:
Ayhan BILIR
1
;
Mine ERGUVEN
;
Ezgi ERMIS
;
Mine SENCAN
;
Nuray YAZIHAN
Author Information
1. Department of Histology and Embryology, Istanbul University Faculty of Medicine, Istanbul, Turkey. bilira@istanbul.edu.tr
- Publication Type:In Vitro ; Original Article
- Keywords:
Endometrial cancer;
Imatinib mesylate;
Lithium chloride;
Medroxyprogesterone acetate;
Midkine
- MeSH:
Benzamides;
Caspase 3;
Cell Cycle;
Cell Proliferation;
Cytokines;
Endometrial Neoplasms;
Endometrium;
Female;
Humans;
Imatinib Mesylate;
Lithium;
Lithium Chloride;
Medroxyprogesterone;
Medroxyprogesterone Acetate;
Mesylates;
Piperazines;
Pyrimidines
- From:Journal of Gynecologic Oncology
2011;22(4):225-232
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The aim of the study was to investigate whether lithium chloride and medroxyprogesterone acetate can potentiate the cytotoxicity of imatinib mesylate in human endometrial cancer in vitro and the effect of midkine in these therapies. METHODS: Imatinib mesylate (50 microM), lithium chloride (100 microM), medroxyprogesterone acetate (200 microM) and their combination were applied to monolayer and three dimensional cultures of human Ishikawa endometrial cancer for 72 hours. The cell proliferation index, apoptotic index, caspase-3 and midkine levels, cell cycle distributions in monolayer cultures and cell ultrastructure in spheroid cultures were evaluated. Results were statistically analyzed using the Student's t-test. RESULTS: All drug applications inhibited cell proliferation (p<0.05), however the combination were the effective groups for 72 hours (p<0.05). Interestingly, although the loss of efficiency was seen higly seen every 24 hours at single applications, the inhibition rates of the combination groups were almost same for 72 hours. In concordance with these results, the apoptotic index, caspase-3 levels (p<0.05), cell morphology and ultrastructure damages were much higher in the combination groups. Imatinib mesylate induced S-phase arrest, however other groups induced G0+G1-phase arrest at 24 hours and all groups induced G0+G1 arrest at 72 hours (p<0.05). Imatinib mesylate and imatinib mesylate with medroxyprogesterone acetate induced highest decrease in midkine levels, respectively (p<0.05). CONCLUSION: The present study showed that the combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro and the inhibition of midkine involved in their mechanism of action against endometrium defense.
